

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1718R1C1

Serial No.

10/607,882

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Vishva Dixit et al

Filing Date

27 Jun 2003

Group

1653

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
gfb	* 1	6,072,047	06.06.00	Rauch et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
gfb	* 2	WO 01/18185	15.03.01	PCT				
	* 3	WO 93/16192	19.08.93	PCT				
	* 4	WO 97/44443	27.11.97	PCT				
	* 5	WO 97/44444	27.11.97	PCT				
	* 6	WO 98/10778	19.03.98	PCT				
gfb	* 7	WO 98/35986	20.08.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


gfb	* 8	Al-Rubeai and Singh, "Apoptosis in cell culture" <u>Curr. Opin. Biotech.</u> 9:152-156 (1998)
	* 9	Ashkenazi and Dixit., "Death Receptors: Signaling and Modulation." <u>Science</u> . 281(5381):1305-1308 (1998)
	*10	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
	*11	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
	*12	Beidler et al., "The Baculovirus p35 Protein Inhibits Fas- and Tumor Necrosis Factor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 270:16526-16528 (1995)
	*13	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
	*14	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
	*15	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)
	*16	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)
	*17	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)
	*18	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)
	*19	Clem et al., "Prevention of Apoptosis by Baculovirus Gene During Infection of Insect Cells" <u>Science</u> 254:1388-1390 (1991)
gfb	*20	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)

Examiner

Date Considered

29 Nov. 2005

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1718R1C1

Serial No.

10/607,882

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Vishva Dixit et al

Filing Date

27 Jun 2003

Group

1653

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*21	Database WPI Section Ch. Week 199715, Derwent Publications Ltd., London, GB; Class B04, AN 1997-380167 (June 24, 1997)
*22	Dickson, A. J., "Apoptosis regulation and its applications to biotechnology" <u>TIBTECH</u> 16:339-342 (1998)
*23	Duan et al., "ICE-LAP6, a Novel Member of the ICE-Ced-3 Gene Family, Is Activated by the Cytotoxic T Cell Protease Granzyme B" <u>Journal of Biological Chemistry</u> 271(28):16720-16724 (1996)
*24	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)
*25	Franeek and Chladkova-Sramkova, "Apoptosis and nutrition: Involvement of amino acid transport system in repression of hybridoma cell death" <u>Cytotechnology</u> 18:113-117 (1995)
*26	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)
*27	Fujita et al., "Overexpression of bcl-2 Improved Survival of COS-1 Cells and Enhanced Transient Protein Production" <u>Journal of Fermentation and Bioengineering</u> 82(6):589-591 (1996)
*28	Fujita et al., "Reinforcing apoptosis-resistance of COS and myeloma cells by transfecting with bcl-2 gene" <u>Cytotechnology</u> 25:25-33 (February 1997)
*29	Goswami et al., "Apoptosis in Batch Cultures of Chinese Hamster Ovary Cells" <u>Biotechnol. Bioeng.</u> 62:632-640 (1999)
30	H.-G. Wang et al., "R-Ras Promotes Apoptosis Caused by Growth Factor Deprivation Via a Bcl-2 Suppressible Mechanism" <u>The Journal of Cell Biology</u> 129(4):1103-1114 (May 1995)
*31	Hedge et al., "Blk, a BH3-containing Mouse Protein That Interacts with Bcl-2 and Bcl-xL, Is a Potent Death Agonist" <u>The Journal of Biological Chemistry</u> 273(14):7783-7786 (April 3, 1998)
*32	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)
*33	Itoh et al., "Overexpression of bcl-2, Apoptosis Suppressing Gene: Prolonged Viable Culture Period of Hybridoma and Enhanced Antibody Production" <u>Biotechnol. Bioeng.</u> 48:118-122 (1995)
*34	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis." <u>Cell</u> 66:233-243 (1991)
*35	Li et al., "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade" <u>Cell</u> 91:479-489 (November 14, 1997)
*36	Mastrangelo and Betenbaugh, "Overcoming apoptosis: new methods for improving protein-expression systems" <u>TIBTECH</u> 16:88-95 (1998)
*37	Mercille and Massie, "Apoptosis-Resistant ElB-19K-Expressing NS/O Myeloma Cells Exhibit Increased Viability and Chimeric Antibody Productivity under Perfusion Culture Conditions" <u>Biotechnology and Bioengineering</u> 63(5):529-543 (June 5, 1999)
*38	Mercille and Massie, "Induction of Apoptosis in Nutrient-Deprived Cultures of Hybridoma and Myeloma Cells" <u>Biotechnol. Bioeng.</u> 44:1140-1154 (1994)
*39	Mercille et al., "Dose-Dependent Reduction of Apoptosis in Nutrient-Limited Cultures of NS/O Myeloma Cells Transfected with the ElB-19K Adenoviral Gene" <u>Biotechnology and Bioengineering</u> 63(5):516-528 (A 1999)
*40	Murray et al., "NSO Myeloma Cell Death: Influence of bcl-2 Overexpression" <u>Biotech. Bioeng.</u> 51(3):298-304 (1996)


Examiner

Date Considered

30 Nov 2005

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1718R1C1	Serial No. 10/607,882
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Vishva Dixit et al	
				Filing Date 27 Jun 2003	Group 1653
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*41		Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)			
*42		Nagata, S., "Apoptosis by Death Factor." <u>Cell</u> 88:355-365 (Feb 1997)			
*43		Pan et al., "Caspase-9, Bcl-X _L , and Apaf-1 Form a Ternary Complex" <u>Journal of Biological Chemistry</u> 273(10):5841-5845 (1998)			
*44		Perkins et al., "Overexpression of Apaf-1 Promotes Apoptosis of Untreated and Paclitaxel- or Etoposide-treated HL-60 Cells" <u>Cancer Research</u> 58:4561-4566 (October 15, 1998)			
*45		pFLAG-CMV-2 Expression Vector, SIGMA PRODUCT INFORMATION			
*46		Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
*47		Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 β Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)			
*48		Seol and Billiar, "A Caspase-9 Variant Missing the Catalytic Site Is an Endogenous Inhibitor of Apoptosis" <u>The Journal of Biological Chemistry</u> 274(4):2072-2076 (January 22, 1999)			
*49		Shak et al., "Recombinant Human DNase I Reduces the Viscosity of Cystic Fibrosis Sputum" <u>Proc. Natl. Acad. Sci. USA</u> 87(23):9188-9192 (Dec 1990)			
*50		Simpson et al., "Prevention of Hybridoma Cell Death by bcl-2 During Suboptimal Culture Conditions" <u>Biotechnol. Bioeng.</u> 54:1-16 (1997)			
*51		Singh et al., "Cell Death in Bioreactors: A Role for Apoptosis" <u>Biotechnol. Bioeng.</u> 44:720-726 (1994)			
*52		Singh et al., "Enhancement of Survivability of Mammalian Cells by Overexpression of the Apoptosis-Suppressor Gene bcl-2" <u>Biotechnol. Bioeng.</u> 52:166-175 (1996)			
*53		Soo et al., "Overexpression of bcl-2 inhibits the apoptosis in rCHO" <u>ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, 219TH MEETING OF THE AMERICAN CHEMICAL SOCIETY, SAN FRANCISCO, 26-30 MARCH 2000</u> 219(1-2) (Abstract BIOT 245)			
*54		Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)			
*55		Suzuki et al., "Establishing apoptosis resistant cell lines for improving protein productivity of cell culture" <u>Cytotechnology</u> 23:55-59 (1997)			
*56		Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)			
*57		Terada et al., "Improvement of Mammalian Cell Survival by Apoptosis-Inhibiting Genes and Caspase Inhibitors for Effective Use of Mammalian Cells" <u>Seibutsu-Kogaku Kaishi</u> 77(1):2-11 (January 25, 1999)			
*58		Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)			
*59		Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)			
*60		Tewari et al., "Yama/CPP32 β , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)			
Examiner 				Date Considered 30 Nov. 2005	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

